IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10071155 B1

PDFFull Text
Date of Patent:
Sep. 11, 2018

Filed:

Oct. 02, 2014

Nasal mucosal vaccine composition

Applicant:

Nitto Denko Corporation, Osaka, JP;

Inventors:

Eiji Kiyotoh, Osaka, JP;

Mitsuhiko Hori, Osaka, JP;

Katsuyuki Okubo, Osaka, JP;

Daisuke Asari, Osaka, JP;

Arimichi Okazaki, Osaka, JP;

Masahiro Fukasaka, Osaka, JP;

Kyohei Matsushita, Osaka, JP;

Assignee:

NITTO DENKO CORPORATION, Osaka, JP;

Attorney:

Greenblum & Bernstein, P.L.C.

Primary Examiner:

Brian Gangle

Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/08 (2006.01); A61K 39/09 (2006.01); A61K 39/12 (2006.01); A61K 39/125 (2006.01); A61K 39/13 (2006.01); A61K 39/145 (2006.01); A61K 39/15 (2006.01); A61K 39/165 (2006.01); A61K 39/205 (2006.01); A61K 39/25 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/08 (2013.01); A61K 39/092 (2013.01); A61K 39/12 (2013.01); A61K 39/125 (2013.01); A61K 39/13 (2013.01); A61K 39/145 (2013.01); A61K 39/15 (2013.01); A61K 39/165 (2013.01); A61K 39/205 (2013.01); A61K 39/25 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/575 (2013.01); C12N 2710/16734 (2013.01); C12N 2710/20034 (2013.01); C12N 2720/12334 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18734 (2013.01); C12N 2760/20134 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/32434 (2013.01); C12N 2770/32634 (2013.01); C12N 2770/36234 (2013.01);
Abstract

The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of, and, or a salt thereof.

Find Patent Forward Citations

Loading…